OTCMKTS:RGIN Regenicin (RGIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Regenicin Stock (OTCMKTS:RGIN) Get Regenicin alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume5,000 shsMarket Capitalization$20 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regenicin, Inc. is a biotechnology company focused on regenerative medicine and tissue engineering. The company’s activities center on the development of products intended to help repair or replace damaged human tissue, particularly skin. Its principal product candidate is PermaDerm™, a tissue-engineered skin substitute designed for potential use in treating severe burns, chronic wounds and other conditions involving significant skin loss. Regenicin has described the product as being developed for applications in wound care and reconstructive medicine, although product availability and regulatory status may depend on further development and approvals. Public information about Regenicin’s operations, leadership team and geographic reach is limited. The company has historically operated as a development-stage biotechnology business and has focused primarily on advancing its regenerative-medicine platform rather than reporting a broad commercial product portfolio.AI Generated. May Contain Errors. Read More Receive RGIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGIN Stock News HeadlinesRegenicin Inc.July 15, 2026 | barrons.comMade Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product ApprovalApril 23, 2026 | marketwatch.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)HistoryOctober 20, 2024 | npr.orgNRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comLGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 19, 2024 | foxnews.comHistory of Walmart: Timeline and FactsDecember 9, 2023 | thestreet.comSee More Headlines RGIN Stock Analysis - Frequently Asked Questions How were Regenicin's earnings last quarter? Regenicin Inc. (OTCMKTS:RGIN) released its quarterly earnings data on Wednesday, August, 19th. The company reported $0.00 EPS for the quarter. How do I buy shares of Regenicin? Shares of RGIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regenicin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regenicin investors own include Energous (WATT), Cheniere Energy (LNG), Vital Therapies (VTL), Company Calendar Last Earnings8/19/2020Today9/24/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:RGIN CIK1412659 Webwww.regenicin.com Phone(732) 757-5500FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares165,770,000Free FloatN/AMarket Cap$20 thousand OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:RGIN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, man...Trading Wire | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...Chaikin Analytics | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regenicin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regenicin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
